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Abstract
Purpose Dabigatran etexilate is an oral, reversible, direct
thrombin inhibitor licensed for the prevention of venous
thromboembolism and stroke prevention in patients with
atrial fibrillation. The aim of this study was to investigate
whether, and to what extent, a switch from enoxparin to
dabigatran etexilate affects the pharmacokinetic (PK) and
pharmacodynamic (PD) parameters and safety profile of
dabigatran.
Methods Enoxaparin 40 mg was administered subcutane-
ously once daily for 3 days followed by a single dose of
dabigatran etexilate 220 mg (test treatment) on day 4 in an
open-label, two-way cross-over trial in healthy volunteers.
Dabigatran plasma levels were measured using a validated
high-performance liquid chromatography tandem mass
spectrometry method. Anticoagulant activity was measured
using a number of clotting tests, including prothrombinase-
induced clotting time (PiCT), activated partial thromboplas-
tin time (aPTT), ecarin clotting time (ECT), and diluted
thrombin time (dTT).
Results PK,PD,andsafetydatawereavailablefor23subjects
for each treatment. The adjusted geometric mean test/refer-
ence ratio of area under the concentration–time curve for total
dabigatran was 84% (90% confidence interval 67.2–105.0%)
and 86% (67.0–110.0%) for maximum plasma concentration.
The PiCT test/reference ratio, which represents the activity of
enoxaparin and dabigatran, was elevated by approximately
15% for peak maximum effect ratio to baseline and total area
under the effect curve (AUEC0-48) activity, suggesting that
some anticoagulant activity of enoxaparin was still present.
Enoxaparin pre-treatment increased the AUEC0–48 of activat-
ed partial thromboplastin time by approximately 14%. All
other dabigatran-related PD markers were unaffected. Tolera-
bility was good, with only mild and reversible adverse events
during the treatment.
Conclusion Prior administration of enoxaparin did not
meaningfully affect the PK or PD properties of dabigatran,
and the switch from enoxaparin to dabigatran etexilate was
well tolerated among the study subjects. These data support
the safety of switching patients from enoxaparin to dabiga-
tran etexilate.
Keywords Enoxaparin.Dabigatranetexilate.Switch.
Pharmacokinetics.pharmacodynamics
Introduction
The benefits of antithrombotic therapy for preventing and
treating venous thromboembolism (VTE) are well docu-
mented, and guidelines for treatment and prophylaxis have
been developed by the American College of Chest
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organizations to optimize patient management [1–6]. Dabi-
gatran etexilate is a new, reversible, and direct thrombin
inhibitor that is administered orally as a pro-drug and rap-
idly converted to the active form, dabigatran.
Dabigatran etexilate has been evaluated in Phase III trials
for a number of indications. It has been found to have
potential advantages during prolonged oral prophylactic
therapy without the requirement for anticoagulation moni-
toring. In addition, as dabigatran etexilate has a rapid onset
of action and can be given at fixed doses, its use can
simplify treatment paradigms. This drug is licensed in >75
countries for the prevention of VTE following elective total
hip or knee replacement surgery, including European
countries [7] and Canada [8]. Dabigatran etexilate is also
being investigated for the treatment and secondary preven-
tion of VTE. In terms of the prevention of stroke or systemic
embolism in patients with atrial fibrillation, dabigatran has
shown superior efficacy compared with warfarin, with an
improved safety profile [9, 10], and its use is approved for
this indication in many countries, including the USA, Can-
ada, Japan, Australia, and the European Union [8, 11, 12].
The replacement of a parenteral anticoagulant by an oral
one, such as dabigatran etexilate, can potentially result in an
easier and more successful implementation of prolonged
prophylaxis. Studying the pharmacokinetic (PK) and phar-
macodynamic (PD) parameters of dabigatran following this
switch will contribute to our knowledge of this drug and,
consequently, to the determination of whether it is a safe and
effective treatment option.
Dabigatran conjugated with activated glucuronic acid
forms a pharmacologically equipotent glucuronide that repre-
sents approximately 20% of total dabigatran exposure in
plasma [13]. Hence, the sum of both free and conjugated
dabigatran (total dabigatran) represents the appropriate corre-
late with PD. PD and dabigatran concentrations are closely
correlated. The objective of this study was to investigate
whether, and to what extent, a change from multiple subcuta-
neous (s.c.) doses (steady-state conditions) of enoxaparin
40 mg once daily to a single oral dose of dabigatran etexilate
220 mg affects the PK/PD parameters of dabigatran.
Methods
Study design and treatments
This study was a single-center, open-label, two-way cross-
over trial conducted in healthy men and women. The aim was
to investigate the influence of a change from multiple s.c.
daily doses of 40 mg enoxaparin to a single oral dose of
220 mg dabigatran etexilate on the relative bioavailability
and PD parameters of dabigatran etexilate. It was designed
to include 24 healthy male and female subjects, with at least
ten of each gender. The trial was carried out in accordance
with the Declaration of Helsinki (1996 version) and the Inter-
national Conference on Harmonization Harmonized Tripartite
Guideline for Good Clinical Practice (GCP). The study was
sponsored by Boehringer Ingelheim Pharma GmbH & Co.
KG, Biberach, Germany.
Dabigatran etexilate (Pradaxa) was supplied by Boeh-
ringer Ingelheim Pharma GmbH & Co. KG and was admin-
istered as a salt of methanesulphonic acid. For enoxaparin,
commercially available Clexane prefilled syringes (pro-
duced by Sanofi-Aventis Deutschland GmbH, Frankfurt
am Main, Germany) were used.
Each subject was allocated to one of two possible treat-
ment sequences and was to receive each of the following
treatments in a cross-over fashion: (1) enoxaparin 40 mg
administered s.c. once daily for 3 days followed by a single
dose of oral dabigatran etexilate 220 mg 24 h later on day 4
(test treatment) or (2) a single dose of dabigatran etexilate
220 mg, without prior enoxaparin administration (reference
treatment). Cross-over treatment periods were separated by
a wash-out phase of 5 days.
The trial comprised four visits. A screening examination
(visit 1) was performed within 21 days before the first admin-
istration of the drug. During visits 2 and 3, the subjects were
treated with either three daily doses of enoxaparin (days –3, –
2, and –1), followed by a single dose of dabigatran etexilate
(day 1), or a single dose of dabigatran etexilate alone in the
morning (day 1). An end-of-study examination (visit 4) was
performed within 7 days after completion of visit 3.
For the dabigatran etexilate treatment, subjects were dis-
charged from the trial site on day 2. On day 3, the subjects
returned for PK/PD blood sampling and an assessment of
tolerability. For the enoxaparin/dabigatran etexilate treatment,
subjects came to the trial site on days −3,−2, and −1 and were
administered enoxaparin s.c. followed by dabigatran etexilate
24 h later (on day 1). PK/PD blood sampling and an assess-
ment of tolerability were undertaken on days 1 to 3.
Subjects
Healthy male or female subjects [based upon complete med-
ical history, physical examination, vital signs (blood pressure,
pulse rate), 12-lead electrocardiogram (ECG), clinical and
laboratory tests], aged ≥18 and ≤55 years with a body mass
index (BMI) between ≥18.5 and ≤29.9 kg/m
2 were included
into the trial. Participants gave their written informed consent
in accordance with GCP and local legislation.
The exclusion criteria included any of the following:
gastrointestinal, hepatic, renal, respiratory, cardiovascular,
metabolic, immunologic or hormonal disorders, history of
bleeding, or intake of medication which might influence
clotting.
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The primary PK endpoints were area under the concentra-
tion–time curve (AUC0–∞) and maximum plasma concen-
tration Cmax) for free and total dabigatran. Primary PD
endpoints were area under the effect curve (AUEC0–48)
and maximum effect ratio to baseline (ERmax) of the com-
bined anticoagulation activities of dabigatran and/or enox-
aparin determined by the prothrombinase induced clotting
test (PiCT) assay, as this assay is sensitive to both factor Xa
inhibition and thrombin inhibition.
Secondary endpoints included other PK and coagulation
parameters: diluted thrombin time (dTT), measured by HEMO-
CLOT (HYPHEN Biomed, Neuville sur Oise, France), activat-
ed partial thromboplastin time (aPTT), and ecarin clotting time
(ECT), for dabigatran, plus PiCT for enoxaparin. Relative
bioavailability and relative PiCT of the test treatment were
compared with the reference treatment. Safety and tolerability
were also secondary endpoints in this trial.
PK/PD determinations
Blood samples for dabigatran PK measurements were col-
lected at −73.0 (before enoxaparin administration) and
−1.0 h (before dabigatran etexilate administration) and at
0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, and 48 h after the
administration of dabigatran etexilate. Plasma concentra-
tions of free, non-conjugated dabigatran, total dabigatran
[sum of free and conjugated dabigatran (measured after
alkaline cleavage of conjugates)], and the metabolites were
determined by a validated high-performance liquid chroma-
tography tandem mass spectrometry method at AAI Pharma
Deutschland GmbH & Co. KG, Neu-Ulm, Germany.
Briefly, for the determination of free dabigatran, 50 μLo f
plasma was diluted with 50 μL of 0.2 M ammonium formate
buffer (pH 3.5), spiked with 40 μL internal standard solution
(100 ng/mL [
13 C6]-dabigatran), mixed, and centrifuged. For
the determination of total dabigatran, 50 μLo fp l a s m aw a s
spiked with 40 μL internal standard solution and mixed with
20 μL of 0.2 M sodium hydroxide. After 2 h of incubation at
37°C, the samples were acidified with 30 μLo f0 . 2Mh y d r o -
gen chloride, mixed, and then centrifuged.
The calibration curves for freeand total dabigatran covered
a range from 1.00 to 400 ng/mL plasma in undiluted samples.
The calibration curves were linear over the calibration range.
The validation data demonstrated adequate selectivity, accu-
racy (−4.54% at maximum) and precision [coefficient of
variation (CV) of 5.28% at maximum] of the assay.
The prolongation of clotting times was calculated for each
standard or trial sample in each assay. For all PD measure-
ments,dabigatranstandardsatconcentrationswithinthe range
0.47–472 ng/mL were used for quality control purposes. For
all PD measurements, one dabigatran quality control sample
wasmeasuredatthebeginning,inthemiddle,andattheendof
the test phase of a day for quality control purposes. The mean
CV of each coagulation time parameter across batches of
quality control samples was <5%. The analysis of the coagu-
lation parameters PiCT, dTT, aPTT, and ECT was performed
by biochemA GmbH, Riegel, Germany. The determination of
all clotting times was performed using a Merlin MC10 PLUS
coagulometer (serial nos. 06 C 10004 and 08 C 10031; MER-
LIN Medical, Lemgo, Germany). For PK/PD correlations,
blood plasma concentrations and coagulation times were
analyzed in parallel.
The Pefakit PiCTassay (Pentapharm, Basel, Switzerland)
was used to measure both factor Xa inhibition and thrombin
inhibition by either dabigatran and/or enoxaparin and was
performed according to the manufacturer’s instructions.
Briefly, a platelet-poor plasma sample (50 μL) was mixed
with 50 μL of R1 activator reagent containing phospholipids
and Russel’s viper venom (factor V activator). After an
incubation period (3 min at 37°C), the added factor Xa is
inhibited depending on the amount of antithrombin–heparin
complexes and/or direct factor Xa and/or factor IIa inhib-
itors present in the sample. The measurement is then initi-
ated by the addition of R2 Start Reagent (50 μL; 25 mM
CaCl2). Following recalcification, the prothrombinase com-
plex is formed using the residual factor Xa, phospholipids,
factor Va generated from factor V present in the sample, and
free calcium ions. Due to preactivation by factor V, pro-
thrombinase formation is not dependent on endogenous
thrombin-mediated factor V activation, resulting in this as-
say being named the “Prothrombinase-induced Clotting
Time” (PiCT) assay. The time lag between the addition of
CaCl2 and clot formation is detected in seconds as the PiCT,
and we used these data in the final presentation of the data.
The dTT was measured using the HEMOCLOT thrombin
inhibitor assay (HYPHEN BioMed, Neuville sur Oise,
France) according to the manufacturer’s instructions. This
assay is used for the quantitative measurement of dabigatran
in plasma (within the range 50–500 ng/mL), with a clotting
method based on the inhibition of a constant and defined
concentration of thrombin. Briefly, diluted test plasma (50
μL plasma sample+350 μL 0.9% NaCl) was mixed with the
normal pooled human plasma provided in the HEMOCLOT
assay kit (reagent R1) and incubated (2 min at 37°C). Clotting
is initiated by adding a constant amount of highly purified
human α-thrombin (reagentR2),and the timelag between the
addition of R2 and the clot formation is detected in seconds as
clotting time and used in the final presentation of the data.
To measure aPTT, we added a kaolin–cephalin reagent,
which is a mixture of cephalin and microcrystalline kiesel-
guhr (75 μL), to the plasma sample (75 μL) and incubated
the mixture at 37°C for 3 min under continuous stirring.
Subsequent addition of CaCl2 solution (0.025 M) activated
the endogenic clotting system, leading to fibrin formation.
Eur J Clin Pharmacol (2012) 68:607–616 609The time from the addition of CaCl2 to the formation of a
fibrin clot was measured as aPTT and used in the final
presentation of the data. The reagent kit was from Roche
Diagnostics GmbH (Mannheim, Germany).
The ECT assay is based on the properties of ecarin, a
metalloprotease isolated from the venom of the saw-scaled
viper Echis carinatus, which generates meizothrombin from
prothrombin by specific cleavage of prothrombin at Arg
320. The procoagulant activity of meizothrombin is low,
amounting to approximately 10% of the equimolar thrombin
mass, making the assay less sensitive than a direct assay of
thrombin activity. The assay procedure was as follows: a
plasma sample (75 μL) was added to imidazole/Veronal
buffer (75 μL) and incubated for 2 min at 37°C. The mea-
surement is initiated by the addition of 75 μL (6 U/mL)
ecarin solution (Pentapharm), leading to conversion of pro-
thrombin into thrombin. The time lag between the addition
of ecarin and the clot formation is detected as ECTand used
in the final presentation of the data.
Safety
The evaluation of safety was based on the incidence of
adverse events (AEs), physical examinations, measurement
of vital signs (blood pressure, pulse rate), 12-lead ECGs,
clinical laboratory tests (hematology, clinical chemistry, and
urinalysis), local tolerability, and a global assessment of
tolerability by the investigator.
Statistical methods
Point estimators [geometric means (gMean)] of the median
intra-subject ratios (with/without enoxaparin pre-treatment)
of AUC0-∞,C max, AUEC0-48,a n dE R max, and their two-
sided 90% confidence intervals (CIs) were calculated. This
study was designed as a relative bioavailability study in a
cross-over fashion, which is considered to be the most
appropriate design to investigate drug interactions. The sta-
tistical model was an analysis of variance (ANOVA) on log-
transformed parameters, including effects for “sequence”,
“subjects nested within sequences”, “period”,a n d“treat-
ment”. CIs were based on the residual error from the
ANOVA and were used to estimate the probability of inter-
action between the two drugs. For all other parameters,
descriptive statistics were calculated.
Results
Subjects
A total of 24 subjects entered the trial (11 women, 13 men),
but one male subject was withdrawn before administration
of the first dose due to an AE. PK, PD, and safety data were
available for 23 subjects during each treatment sequence.
Overall, the mean (± standard deviation) age of the 23
subjects was 38.4±8.5 years, and the BMI was 23.38±
2.23 kg/m
2.
PK parameters
The administration of the last dose of enoxaparin 24 h prior
to dabigatran etexilate 220 mg did not markedly affect the
plasma concentration–time profile of total dabigatran
(Fig. 1). Similar profiles were also observed for plasma
concentrations of free dabigatran.
There was no clinically relevant effect of enoxaparin pre-
treatment on the PK of total or free dabigatran (Table 1). The
exposure to dabigatran after the switch from enoxaparin was
slightly lower compared to the reference treatment without
enoxaparin pre-treatment (Table 1). The test/reference ratio
of AUC0–∞ for total dabigatran was 84% (90% CI 67.2–
105.0) and that for Cmax was 86% (90% CI 67.0–110.0),
representing an average decrease of approximately 15% in
the bioavailability of dabigatran 24 h after pre-treatment
with enoxaparin. The values for time from dosing to max-
imum plasma concentration and terminal half-life were sim-
ilar for both treatment periods. The ratio of free to total
dabigatran gMean AUC0-∞ was not changed by the enox-
aparin pre-treatment (dabigatran alone 0.760; after enoxa-
parin 0.765).
PD parameters
The effect–time profiles for PiCT, aPTT, ECT, and dTT
are shown in Fig. 2. When dabigatran etexilate was
dosed 24 h after enoxaparin, the PiCT ratio to baseline
curve was more pronounced than that with the adminis-
tration of dabigatran alone. The time to peak was similar
(3 h) in both treatment regimens, but there was a slight
elevation of the time to clotting at all time points in the
former when compared to those obtained with dabigatran
alone. This slight elevation of approximately 15% was
Dabigatran etexilate alone
Dabigatran etexilate after enoxaparin
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610 Eur J Clin Pharmacol (2012) 68:607–616relatively consistent over time. Using the primary end-
points measured over the entire 48-h time period, the
test/reference ratio for AUEC0–48 was 163.7% (90%CI
114.3−234.3), an increase of approximately 64%, and
the ratio for ERmax was 115.2% (90% CI 101.8−130.4),
an increase of approximately 15% compared with dabi-
gatran etexilate alone. Mean PiCT levels were higher in
female than in male subjects (data not shown).
The dTT and ECT only measure the specific effects of
antithrombin activity—the former by adding exogenous
thrombin to diluted plasma and the latter by activating
endogenous thrombin, thus bypassing any effect of factor
Xa inhibition. These coagulation parameters were not mean-
ingfully affected by enoxaparin (Fig. 2).
The aPTT assay is a performance indicator of the efficacy
of the intrinsic pathway of the coagulation cascade, involving
factors I, II, V, VIII, IX X, XI, and XII. Enoxaparin pre-
treatment increased the AUEC0–48 of aPTT by approximately
14% (Table 2), and except for a slight discrepancy in anti-
coagulationat12h,theaPTTratio curvesfordabigatranalone
and dabigatran after enoxaparin were almost superimposable
(Fig. 2).
PK/PD correlation
Evaluation of the PK/PD revealed a curvilinear relationship
between plasma concentration and coagulation prolongation
for aPTT (Fig. 3a). No effect of enoxaparin on the PK/PD
relationship of aPTT was found when dabigatran etexilate
was given alone or in combination with enoxaparin. The
PiCT assay also exhibited a curvilinear relationship with
plasma concentrations of dabigatran (Fig. 3b). A slight shift
of the curve was observed when dabigatran etexilate was
administered after enoxaparin, due the slight elevation of
time to clotting observed with this assay (Fig. 1).
Safety
The occurrence of AEs is shown in Table 3. Eight subjects
reported a total of 12 AEs, two of which were considered
treatment-related. The AEs reported during treatment were
headache (3 subjects), fatigue (2 subjects), back pain (2
subjects), diarrhea, hematoma, epistaxis, rash, and increase
in hepatic enzymes (1 subject each). Of these, all but one AE
were of mild nature. The increase in hepatic enzymes during
treatment with enoxaparin + dabigatran in one subject was
considered moderate. This patient already had a slight ele-
vation at baseline; on re-testing after 10 days the levels had
returned to baseline. There were no serious AEs or AEs of
severe intensity during treatment.
The actual treatment at onset of the AEs was dabigatran
in three subjects (13.0%), enoxaparin in four subjects
(17.4%), and enoxaparin + dabigatran in three subjects
(13.0%). One subject experienced a serious AE during the
post-study period, approximately 7 weeks after the last dose.
The event (ischemic stroke) required hospitalization but was
not considered to be related to the study treatments. There
were no clinically relevant differences in other safety param-
eters. Tolerability was described as “good” for both
treatments.
Discussion
Guidelines for VTE prevention currently recommend thera-
py with a low-molecular-weight heparin (LMWH), fonda-
parinux, or low-dose unfractionated heparin. For high-risk
patients, such as those undergoing total hip or knee arthro-
plasty, pharmacological thromboprophylaxis should be con-
tinued for at least 10—and up to 35—days [1–4]. For acute
treatment of VTE, unfractionated heparin, LMWH, or
Table 1 Adjusted by-treatment geometric means and relative bioavailability of dabigatran (total and free) after administration of dabigatran
etexilate 220 mg, with and without enoxaparin (n023)
Analyte Parameter gMean Ratio test/
reference (%)
90% Confidence
interval
Intra-individual
gCV (%)
Test
a
(n023)
Reference
b
(n023)
Lower
limit
Upper
limit
Total dabigatran AUC0-∞ (ng·h/mL) 774.2 921.7 84 67.2 105.0 46.1
Cmax (ng/mL) 99.0 115.3 86 67.0 110.0 51.9
Free dabigatran AUC0-∞ (ng·h/mL) 591.7 700.1 85 67.5 105.9 46.6
Cmax (ng/mL) 78.4 90.7 86 67.5 110.8 51.9
gMean, Geometric mean; AUC0–∞, area under the concentration–time curve; Cmax, maximum plasma concentration; gCV, geometric coefficient of
variation
aTest: dabigatran etexilate after 3-day subcutaneous treatment with enoxaparin
bReference: dabigatran etexilate alone
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612 Eur J Clin Pharmacol (2012) 68:607–616fondaparinux is recommended for at least 5 days; an oral
vitamin K antagonist should be initiated in parallel, and the
injectable therapy can be stopped when the international
normalized ratio (INR) has reached≥2 for at least 24 h. Oral
therapy is then continued for months to years, according to
patient risk factors, to prevent secondary recurrence [3–6].
Thus, when longer term anticoagulant therapy is indicated,
or when treatment is to continue out of hospital for more
than a few weeks, patients are usually switched from a
parenteral to an oral anticoagulant due to the inconvenience
of parenteral administration [3–6].
Until recently, warfarin or other vitamin K antagonists
were the only available oral anticoagulants. However, their
use is limited by slow onset of action, variability of effect,
frequent INR testing, and need for dosage adjustment. As a
result, therapy is not always provided or continued for the
recommended duration, putting patients at risk.
This study addressed the feasibility of switching from the
LMWH enoxaparin to oral therapy with the direct thrombin
inhibitor dabigatran etexilate. The doses and administration
schedules selected for this trial reflect the European standard
clinical doses for primary VTE prevention in the orthopedic
setting. Enoxaparin is generally administered at a daily dose
of 20 or 40 mg s.c. [15]. The dabigatran etexilate dose
administered in this trial (220 mg as a single oral dose) is
the higher of two once-daily doses approved by the Euro-
pean Commission for the prevention of VTE in patients
undergoing hip or knee surgery.
In the current study, 3-day treatment with enoxaparin
40 mg once daily followed 24 h later with dabigatran etex-
ilate resulted in small reductions in dabigatran exposure
(AUC0–∞ and Cmax). However, the 90% CI around the
intra-subject test/reference ratios included the value 100%,
and the ratios of free versus total dabigatran were not
changed by pre-treatment with enoxaparin. After a single
dose of dabigatran etexilate, the intra-subject variability was
relatively high (in this study>40% for AUC and Cmax) and,
due to the study sample size, it was not expected to be
possible to demonstrate equivalence of exposure between
the drug administered alone or after enoxaparin. The slight
reduction in dabigatran exposure by approximately 15%,
however, provides evidence that pre-treatment with
Table 2 Pharmacodynamic parameters after the administration of dabigatran etexilate 220 mg, with and without enoxaparin (n023)
a
Pharmacodynamic parameters Dabigatran etexilate alone Dabigatran etexilate
after enoxaparin
Ratio of adjusted test/reference
[ gMean, % (90% CI)]
gMean gCV (%) gMean gCV (%)
PiCT
Ebase (s) 28.4 18.7 34.7
c 10.6
AUEC0–48 (h) 14.6 112 23.8
c 60.4 163.7 (114.3–234.3)
ERmax 2.53 33.0 2.92
c 30.0 115.2 (101.8–130.4)
aPTT
Ebase (s) 39.1 26.1 39.3 30.9
AUEC0–48 (h) 5.65 106 6.56 131 114.2 (75.1–173.5)
ERmax 2.40 47.9 2.07 47.6 84.9 (70.3–102.5)
ECT
Ebase (s) 33.1 12.8 32.6
d 8.96
AUEC0–48 (h) 7.28 123 7.30 94.3 99.2 (67.8–145.0)
ERmax 2.25 37.7 2.05 38.1 91.0 (80.0–103.5)
dTT (HEMOCLOT)
b
Ebase (s) 31.7 1.67 31.0 3.24
AUEC0–48 (h) 4.01 84.2 3.61 99.5 88.4 (66.8–116.9)
ERmax 1.64 26.6 1.55 28.2 95.0 (87.4–103.2)
PiCT, Prothrombinase-induced clotting time; Ebase, baseline effect; AUEC0–48, area under the effect-time curve from 0 to 48 h after administration;
ERmax, maximum effect ratio to baseline; aPTT, activated partial thromboplastin time; ECT, ecarin clotting time; for other pharmacodynamic
parameters, see footnote of Table 1
aAll of the PD assays have previously been calibrated with dabigatran standards at concentrations within the range 0.47–472 ng/mL, and therefore
within the expected dabigatran plasma levels [14]. For the purposes of this study, one standard was prepared at a concentration of 142 ng/mL; this
quality control sample was measured at the beginning, middle, and end of the test phase of each day.
bdTT, Diluted thrombin time, measured using the HEMOCLOT thrombin inhibitor assay (HYPHEN BioMed, Neuville sur Oise, France)
cn021;
dn022
Eur J Clin Pharmacol (2012) 68:607–616 613enoxaparin has no clinically meaningful effect on the PK of
dabigatran.
Prolongation in the PiCT assay can result from both
factor Xa inhibition and thrombin inhibition, since coagula-
tion is preactivated in the prothrombinase complex by direct
factor V activation. Thus, this assay has the potential to
reflect the anticoagulant effect of both enoxaparin and dabi-
gatran. There was an approximate 15% elevation of antico-
agulant activity (ERmax) in the subjects receiving dabigatran
24 h after enoxaparin as compared with those receiving
dabigatran alone. This elevation most likely demonstrates
the additive effect of dabigatran anticoagulant activity and
residual anticoagulant activity from enoxaparin. The rela-
tively large calculated primary endpoint of 64% elevation of
PiCT AUEC0–48 with enoxaparin pre-dosing also reflects
the very long measurement period of 48 h and amplifies
even very small differences between the two curves. The
approximate 15% increase in ERmax probably more appro-
priately reflects the real remaining effect of enoxaparin, and
this elevation is not considered clinically relevant (Fig. 2).
It is also worth considering that the PiCTassay may not be
the most appropriate assay for dabigatran quantitation.
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Table 3 Number of adverse events reported
Adverse
events
Treatment at onset (n023)
Dabigatran
etexilate alone
Enoxaparin Dabigatran etexilate
after enoxaparin
Headache 1 2 –
Diarrhea 1 ––
Back pain 1 – 1
Hematoma – 1 –
Epistaxis – 1
a –
Fatigue – 2 –
Rash –– 1
Elevated liver
enzymes
– 1
a
aConsidered to be drug-related
614 Eur J Clin Pharmacol (2012) 68:607–616Calibration curves constructed for dabigatran (data not
shown) highlighted a non-linear quantitation with poor preci-
sion and accuracy. Enoxaparin calibration curves, by contrast,
showed a linear relation between PiCT values and enoxaparin
concentration with good accuracy (data not shown).
By contrast, assays that focus predominantly on anti-
thrombin activity, such as the dTT, which adds exogenous
thrombin to diluted plasma, or the ECT, which activates
prothrombin independently of the prothrombin complex,
showed no difference in the anticoagulant effect with or
without prior enoxaparin treatment. These data are also con-
sistent with the plasma level results measured with LC-MS/
MS. Although enoxaparin also has anti-thrombin activity
(mean anti-factor Xa/IIa ratio 14.0±3.1) [16], this level was
either too low to be detectable or these clotting assays are not
sensitive enough to detect it. Furthermore, the relative contri-
butionofenoxaparin’santi-thrombinactivityistoosmalltobe
relevant 24 h after enoxaparin has been administered. This is
consistent with the mechanism of action of dabigatran and
correlates well with the results obtained.
No drug-related AEs, such as any bleeding or hematoma,
were observed during the treatment with dabigatran etexilate
after enoxaparin. Overall, a moderate increase in PiCT 24 h
after the switch from enoxaparin to dabigatran, as observed
in this trial, is not considered to be clinically meaningful.
Additionally, supportive clinical experience regarding
switching was observed in another clinical setting, the treat-
ment of VTE. In the phase III RE-COVER study, all sub-
jects received a parenteral anticoagulant (mostly LMWH,
which would typically be given at a higher dose than for
primary VTE prevention) as well as either warfarin or war-
farin placebo for at least 5 days (median 9 days) prior to
discontinuing the parenteral anticoagulant and either switch-
ing to dabigatran etexilate 150 mg twice daily or continuing
warfarin in a double-blind, double-dummy fashion. The first
dabigatran etexilate dose was given 0–2 h before the time
when the next dose of the parenteral therapy would have
been due. In this trial, there were fewer major or clinically
relevant non-major bleeding events and similar rates of
major bleeding events for the dabigatran versus the warfarin
group during the 6-month treatment period [17, 18]. This
study highlights the efficacy and safety of switching to
dabigatran etexilate in this patient population, even after
12 h of the last dose of enoxaparin. Furthermore, in patients
with atrial fibrillation, the impact of temporary treatment
interruptions for surgery or a diagnostic procedure was inves-
tigated in the RE-LY trial of dabigatran etexilate 150 or
110mgtwicedaily(doubleblind)versuswarfarin(openlabel)
for stroke prevention in patients with atrial fibrillation [9, 10].
Discontinuation of dabigatran etexilate for between 1 and
5 days was recommended depending on the type of procedure
planned and the anticipated bleeding risk, and short-term
bridging anticoagulant therapy (e.g., unfractionated heparin
and/or LMWH) was used, if appropriate. Temporary interrup-
tions occurred in 4,623 subjects. More subjects in the dabiga-
tran etexilate groups were managed without bridging therapy
(77.4%inthe 150 mgtwice-dailygroup;79.3% inthe 110mg
twice-dailygroup)thaninthe warfaringroup (65.7%).Stroke,
myocardial infarction, and bleeding events occurred at
similar frequencies in all treatment groups within 30 days
of reinitiating study medication [18]. Thus, recommenda-
tions for switching between dabigatran etexilate and a
parenteral anticoagulant resulted in effective and safe man-
agement of patients.
Similarly, in the SPORTIF III and V trials [19, 20], two
Phase III trials for the prevention of stroke and systemic
embolism in patients with atrial fibrillation, patients were
randomized to either warfarin or ximelagatran, another di-
rect thrombin inhibitor. As in the previously described RE-
LY trial, there was a proportion of participants undergoing
interventions during the study who were switched from
enoxaparin to ximelagatran. No safety issue has been
reported in relation to switching from parenteral to oral
anticoagulation in these trials. In another trial of VTE
treatment and secondary prevention, the THRIVE III
study, switching from 6 months of standard parenteral
coagulation therapy to ximelagatran for an additional
18 months effectively prevented recurrences of VTE,
with an incidence of bleeding similar to that in the
placebo group and low overall mortality [21]. Switching
between parenteral and oral anticoagulant therapy was
therefore an effective treatment option. Finally, a clinical
trial investigating the effects of switching from enoxaparin to
the new oral factor Xa inhibitor, rivaroxaban, in patients
undergoing totalhip orkneereplacementhas beencompleted;
however to the best of our knowledge, results have not yet
been published [22].
In summary, in this Phase I study, enoxaparin and
dabigatran etexilate had favorable safety and were well
tolerated; the switch from enoxaparin to dabigatran etexilate
was also well tolerated. These data support the feasibility
and safety of switching from enoxaparin to dabigatran
etexilate.
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